If you liked this article you might like

Akorn Is Highly Coveted, But Tea Leaves Don't Read Bidding War
EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round
Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)
2 Biotech Pullback Targets